4 results match your criteria: "Northern Light Cancer Institute[Affiliation]"
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
NPJ Precis Oncol
March 2024
The Jackson Laboratory, Augusta, ME, USA.
Article Synopsis
- - Genomic tumor testing (GTT) aims to identify specific tumor variants that can be treated with targeted drugs, but access is often limited for rural patients in community oncology settings.
- - In a study involving 1,603 adult cancer patients in Maine, 1,258 had actionable variants identified, leading to 240 genome-matched treatments, with a notable survival benefit for those treated (31% less likely to die within one year).
- - The results indicate that while GTT can provide effective treatment options in rural areas, there is still a need to increase the availability of clinical trials and improve the infrastructure supporting these tests.
The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State.
JCO Precis Oncol
May 2023
The Jackson Laboratory for Genomic Medicine, Farmington, CT.
Article Synopsis
- - The Maine Cancer Genomics Initiative (MCGI) aimed to improve genomic tumor testing access for cancer patients in rural Maine through genomic tumor boards, clinician education, and free testing services from 2016 to 2020.
- - A hub-and-spoke model was adopted for the initiative, involving a centralized genomic tumor board program, an online education module, and comprehensive testing that engaged all 19 oncology practices in Maine, with participation from 79 oncologists.
- - The initiative successfully enrolled 1610 patients, held 196 genomic tumor boards with 47 clinicians, and achieved significant improvements in clinician participation and patient enrollment in a rural setting, enhancing precision oncology accessibility.
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure.
J Clin Transl Sci
June 2021
Department of Medicine, Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.
Background: A feedforward pathological signaling loop generated by TNFα and IFN-γ synergy in the inflamed lung, driving CXCL-10 (IP-10) and CXCL-9 chemokine-mediated activated T-cell and monocyte/macrophage tissue recruitment, may define the inflammatory biology of lethal COVID-19 respiratory failure.
Methods: To assess TNFα-antagonist therapy, 18 hospitalized adults with hypoxic respiratory failure and COVID-19 pneumonia received single-dose infliximab-abda therapy 5 mg/kg intravenously between April and December 2020. The primary endpoint was time to increase in oxygen saturation to fraction of inspired oxygen ratio (SpO2/FiO2) by ≥50 compared to baseline and sustained for 48 h.
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
J Cancer Res Clin Oncol
September 2021
Department of Hematology Oncology, Northern Light Cancer Institute, 33 Whiting Hill Lane, Brewer, ME, 04412, USA.
Background: Given the widespread use of immune checkpoint inhibitors (ICIs), newer immune related adverse events (irAEs) have come to light, including flare-ups of preexisting autoimmune disorders (AIDs) and delayed immune-related events. We aimed to identify the frequency and severity of new IRAEs, including AID flares in cancer patients treated with ICIs at our institution. We also studied the tolerability of ICIs upon rechallenge in patients with irAEs and hospital admissions due to irAEs in a community setting in rural Maine.
View Article and Find Full Text PDF